Analysts/Institutional Investor Meet/Con. Call Updates
- Sayakha facility reaching 65% utilization, driving backward integration and targeting 15-16% EBITDA margins over time.
- Brownfield expansion at Baddi nearly doubling oral solid dosage (OSD) capacity to scale high-margin formulation exports.
- Q1 FY27 operational recovery showing 19% YoY revenue growth and EBITDA margin expansion to 13.8%.
- Reasonable valuation with trailing P/E of 19.8x versus peer median P/E of 35.5x, offering valuation buffer.
- GPCB closure directive issued on July 18, 2026 for Saykha Amines facility creates regulatory compliance and operational risk.
- Volatile raw material prices (20% RM price spike risk) and pricing power limitations in antibiotic APIs.
- Leadership transition effective October 2026 as long-time MD Prakash Patil retires.
- GPCB regulatory notice/closure order for Saykha plant under Section 33A of Water Act (July 2026).
Aarti Drugs (AARTIDRUGS) - Comprehensive Analysis Report
Analysis Date: August 7, 2026
Current Price: ₹416.2 | Market Cap: ₹3,810 Cr | Trailing P/E: 19.8x | Peer Median P/E: 35.5x
1. Catalyst & Con Call Update Overview
On August 7, 2026, Aarti Drugs hosted its earnings call summarizing Q1 FY27 performance and operational updates: - Q1 FY27 Results (disclosed July 31/Aug 1): Revenue grew 19.0% YoY to ₹703.6 Cr, and Net Profit surged 56.8% YoY to ₹55.3 Cr. EBITDA margin improved 120 bps YoY to 13.8%. - Sayakha Amines Facility: Reached 65% capacity utilization. Target is 80–90% captive supply by Q3 FY27 (Dec 2026), expected to structural expand gross margins. - Baddi Formulation Expansion: Brownfield project underway to double Oral Solid Dosage (OSD) capacity. Formulations currently represent ~₹326 Cr annual turnover with 74% export mix. - Priced-In Assessment: TRUE. The headline Q1 financial performance was reported on July 31, 2026 (1 week prior). The con call provides valuable operational incremental updates, but the core financial re-rating trigger was already known.
2. Industry & Fundamental Quality Evaluation
- Industry Structure: API & Bulk Drugs / Formulations. Capital intensity is MEDIUM. Industry structural growth rate is ~8–10% CAGR.
- ROCE & Capital Efficiency: Trailing ROCE is 12.0%, which fails our strict >15% quality gate. D/E stands manageable at 0.30x (Debt ₹421 Cr on Net Worth ₹1,405 Cr).
- SEPA Growth Grade: C. Revenue declined -7.8% in FY25 before rebounding +6.9% in FY26. Q1 FY27 demonstrates sharp acceleration (+19% YoY), indicating cyclical recovery.
3. Ramp-Aware Execution & Financial Impact Math
- Formulation Segment Scaling: Current formulation revenue is ~₹81.6 Cr/quarter (~₹326 Cr annual). Doubling Baddi OSD capacity over 2–3 years adds ~₹200–250 Cr in incremental top-line capacity.
- Backward Integration Impact: Sayakha meeting 80–90% captive intermediate needs can expand consolidated OPM from 12.0% to 14.5–15.0%.
- Revenue Uplift:
- Year 1 Uplift: +6.5% (~₹160 Cr incremental revenue).
- Steady-State Uplift (Year 3): +15.0% (~₹375 Cr incremental revenue, taking revenue to ~₹2,860 Cr).
- EPS Uplift Calculation:
- TTM Revenue: ₹2,492 Cr | TTM PAT: ₹192 Cr | TTM EPS: ₹20.98
- Steady-State Revenue: ₹2,860 Cr
- At 14.5% EBITDA margin and ~8.2% PAT margin, Steady-State PAT = ~₹235 Cr.
- Expected EPS Uplift = +22.0% (to ~₹25.60 EPS).
4. Valuation Scenarios & Horizon (24-36 Months)
- Base Case (30% Upside to ₹541): EPS grows to ₹25.60; P/E re-rates modestly to 21x driven by margin expansion and formulation export scale.
- Bull Case (60% Upside to ₹666): EPS reaches ₹28.50 as EBITDA margins hit 16% target; P/E expands to 23.5x given broader industry re-rating.
- Bear Case (-22% Downside to ₹325): GPCB regulatory issues prolong Sayakha operations or raw material spikes squeeze margins back below 11%; P/E contracts to 15x.
5. Final Verdict & Key Takeaways
- Multibagger Verdict: POSSIBLE (Score: 48/100).
- Rationale: Aarti Drugs is in an operational turnaround phase backed by backward integration and formulation expansion. However, moderate historical ROCE (12%) and recent regulatory friction (GPCB directive on Saykha plant) act as capping constraints.
